Advertisement

Prostatacarcinom

  • Bob Djavan
  • Christian Seitz
  • Michael Marberger
Part of the Onkologie heute book series (ONKOLOGIE)

Zusammenfassung

Das Prostatacarcinom ist eine Erkrankung des älteren Mannes mit einem Häufigkeitsgipfel zwischen dem 7. und dem 8. Dezennium. In der männlichen Bevölkerung der westlichen Industriestaaten steht das Prostatacarcinom hinter dem Bronchuscarcinom an der 2. Stelle der tumorbedingten Todesursachen, wobei es in Österreich sogar die häufigste malignombedingte Todesursache darstellt. Die Inzidenzrate liegt in Europa derzeit bei durchschnittlich 84 pro 100.000 pro Jahr und ist mit einer durchschnittlichen jährlichen Steigerungsrate von 3,7% deutlich im Vormarsch. Ob diese Inzidenzzunahme Ausdruck eines erhöhten Krankheitsrisikos ist oder es sich dabei um eine Verbesserung der Diagnostik handelt, ist noch nicht abschließend geklärt. Fest steht jedoch, daß das PSA einen der wichtigsten Faktoren zum Screening und zur Früherkennung des Prostatacarcinoms darstellt. Wesentlich in der Diagnostik, aber auch in der Therapie des Prostatacarcinoms, ist das biologische Verhalten des Tumors. So besteht eine deutliche Diskrepanz zwischen dem latenten Prostatacarcinom (oder auch dem in einer Autopsie zufällig entdeckten Carcinom), dem diagnostizierten und dem zum Tode führenden Prostatacarcinom. So können latente Prostatacarcinome in Autopsiestudien bei 30% aller Männer zwischen dem 40. und 50. Lebensjahr und bei fast 80% aller Männer über 80 nachgewiesen werden. Die Wahrscheinlichkeit für die Diagnose eines Prostatacarcinoms liegt bei 50jährigen Männern derzeit bei 9,5%; das Risiko, daran zu sterben, bei ca. 3%. Die Mortalität des Prostatacarcinoms ist in der höheren Altersgruppe (70 bis 80jährige) mit 32% am höchsten. Außer familiären Risikofaktoren gibt es eindeutige Hinweise, daß Umweltfaktoren, vor allem Eßgewohnheiten (tierische Fettsäuren), ein erhöhtes Prostatacarcinomrisiko in sich bergen. Rezente Studien konnten zeigen, daß vor allem Phytoöstrogene eine protektive Wirkung auf die Entstehung des Prostatacarcinoms haben.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Abbou CC, Salomon L, Hoznek A, Antiphon P, Cicco A, Saint F, Alame W, Bellot J, Chopin DK (2000) Laparoscopic radical prostatectomy: Preliminary results. Urology 55(5): 630–633.PubMedCrossRefGoogle Scholar
  2. [2]
    Bagshaw MA, Cox RS, Hancock SL (1996) External beam radiotherapy for localized prostatic cancer at Stanford: Update at the 38th year. In: Petrovich Z, Baert L, Brady LW (eds) Carcinoma of the Prostate. Springer, Berlin.Google Scholar
  3. [3]
    Bagshaw MA, Cox RS, Rambakc JE (1990) Radiation therapy for localized prostate cancer: Justification by long term follow up. Urol Clin North Am 17: 787–802.PubMedGoogle Scholar
  4. [4]
    Bagshaw MA, Cox RS, Ray GR (1988) Status of radiation treatment of prostate cancer at Stanford University. NCI Monograph 7: 47–60.Google Scholar
  5. [5]
    Bangma CH, Rietbergen JBW, Kranse R, Blijenberg BG, Petterson K, Schröder FH (1997) The free-to-total prostate specific antigen in screening for prostate cancer in the general population. J Urol 157: 2191–2198.PubMedCrossRefGoogle Scholar
  6. [6]
    Bertermann H, Brix F (1990) Ultrasonically guided interstitial high dose brachy-therapy with iridium-192: Technique and preliminary results in locally confined prostate cancer. In: Martinez, Orton, Mould (eds) Brachytherapy LDR and HDR. Nuclear Corp., Columbia/USA, S. 281–303.Google Scholar
  7. [7]
    Blackard CE, Doe RP, Mellinger GT, Byar DP (1970) Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 26: 249–256.PubMedCrossRefGoogle Scholar
  8. [8]
    Bolla M, Gonzalez D, Warde P (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. NEJM 337: 295–300.PubMedCrossRefGoogle Scholar
  9. [9]
    Boxer R, Kaufman J, Goodwin W (1977) Radical prostatectomy for carcinoma of the prostate: 1951-1976. A review of 329 patients. J Urol 117: 208–213.PubMedGoogle Scholar
  10. [10]
    Brawer MK (1994) Prostate specific antigen: Critical issues. Urology 44: 9.CrossRefGoogle Scholar
  11. [11]
    Brawer MK, Benson MC, Bostwick DG, Djavan B, Lilja H, Semjonow A, Su S, Zhou Z (1999) Prostate-specific antigen and other serum markers: Current concepts from the World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 17(4): 206–221.PubMedGoogle Scholar
  12. [12]
    Bruchovsky N, Goldenberg SL, Gleave M (1997) Intermittend hormonal therapy for prostate cancer. Mosby-Year Book, St. Louis. Advances in Urology 10: 291–326.Google Scholar
  13. [13]
    Byar DP, Corle DK (1988) Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monogr 7: 165–170.PubMedGoogle Scholar
  14. [14]
    Carlson DG, Calvanese CB, Partin AW (1998) Cancer: Results on 4298 cases. Urology 52:455–461.PubMedCrossRefGoogle Scholar
  15. [15]
    Carlton CE, Dawoud F, Hudgins P (1972) Irradiation treatment of carcinoma of the prostate: A preliminary report based on 8 years of experience. J Urol 18: 924–927.Google Scholar
  16. [16]
    Carter HB, Pearson JD (1997) Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin N Amer 24: 333–338.CrossRefGoogle Scholar
  17. [17]
    Catalona W, Basler J (1993) Return of erections and urinary continence following radical retropubic prostatectomy. J Urol 150: 905–907.PubMedGoogle Scholar
  18. [18]
    Crawford ED, Eisenberger MA, McLeod DG, Wikding G, Blumenstein BA (1997) Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: Result of NCI intergroup study 0105 (SWOG and ECOG). J Urol 157(Suppl): 336 (Abstract).Google Scholar
  19. [19]
    Denis LJ, Whelan P, Carneiro de Moura JL, et al., and Members of the EORTC GU Group and EORTC Data Center (1993) Goserelin acetate and flutamide vs. bilateral orchiectomy: A phase III EORTC trial (30853). Urology 42: 119–129.PubMedCrossRefGoogle Scholar
  20. [20]
    Dijkman GA, Debruyne FM (1996) Epidemiology of prostate cancer. Eur Urol 30: 281–295.PubMedGoogle Scholar
  21. [21]
    Djavan B, Bursa B, Hruby S, Marberger M (2000) Minimal invasive Therapiealternativen für lokalisierte Prostatacarcinome. Onkologie 6: 118–122.CrossRefGoogle Scholar
  22. [22]
    Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG (1998) Gleason scores from prostate biopsies obtained with 18-gauche biopsy needles poorly predict. Gleason scores of radical prostatectomy specimens. Eur Urol 33: 261–270.PubMedCrossRefGoogle Scholar
  23. [23]
    Djavan B, Remzi M, Partin AW, Basharkhah A, Zlotta A, Schulman CC, Marberger M (2000) Optimal predictors of prostate cancer in repeat biopsy: A prospective study in 1051 men. J Urol 163(4): 1144–1148.PubMedCrossRefGoogle Scholar
  24. [24]
    Djavan B, Seitz C, Remzi M, Ghawidel K, Basharkhah A, Hruby S, Bursa B, Marberger M (1999) Combinations of PSA based diagnostic tests for prostate cancer detection. Tech Urol 5(2): 71–76.PubMedGoogle Scholar
  25. [25]
    Djavan B, Susani M, Shariat S, Zlotta AR, Silverman D, Schulman CC, Marberger M (1998) Transperineal radiofrequency interstitial tumor ablation (RITA) for localized prostate cancer. Tech Urol 4(2): 103–109.PubMedGoogle Scholar
  26. [26]
    Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M (1998) Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 160: 411–418.PubMedCrossRefGoogle Scholar
  27. [27]
    Djavan B, Zlotta AR, Kratzik C, Remzi M, Seitz C, Schulman CC, Marberger M (1999) PSA density, PSA density of transition zone, free to total PSA ratio and PSA velocity for prostate detection in men with total of 2.5 to 4 ng/ml. Urology 54: 517–522.PubMedCrossRefGoogle Scholar
  28. [28]
    Djavan B, Zlotta AR, Shariat S, Omar M, Schulman CC, Marberger M (1998) PSA density of the transition zone for prostate cancer prediction. J Urol 160(2): 411–418.PubMedCrossRefGoogle Scholar
  29. [29]
    Eisenberger MA, Sinibaldi VJ, Reyno LM (1995) Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13: 2174–2186.PubMedGoogle Scholar
  30. [30]
    Epstein BE, Hanks GE (1992) Prostate cancer: Evaluation and radiotherapeutic management. Ca-Cancer J Clin 42: 223–240.PubMedCrossRefGoogle Scholar
  31. [31]
    Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS (1998) National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening. Urology 52: 448–449.CrossRefGoogle Scholar
  32. [32]
    Guilloneau B, Vallancien G (2000) Laparoscopic radical prostatectomy: The Montsouris technique. J Urol 163(6): 1643–1649.CrossRefGoogle Scholar
  33. [33]
    Guilloneau B, Vallancien G (2000) Laparoscopic radical prostatectomy: The Montsouris experience (2000). J Urol 163(2): 418–422.CrossRefGoogle Scholar
  34. [34]
    Hammerer PG, McNeal JE, Stamey TA (1995) Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 153: 111–114.PubMedCrossRefGoogle Scholar
  35. [35]
    Hamper UM, Shet S, Walsh PC (1991) Capsular transgression of prostatic carcinoma: Evaluation with transrectal US with pathologic correlation. Radiology 178: 791–795.PubMedGoogle Scholar
  36. [36]
    Hanks GE, Lee WR, Hanlon AL (1996) Conformai technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml. Int J Radiat Oncol Biol Phys 35: 861–868.PubMedCrossRefGoogle Scholar
  37. [37]
    Hanks GE, Martz KL, Diamond JJ (1988) The effect of dose on local control of prostate cancer. Int J Rad Oncol Biol Phys 15: 1299.CrossRefGoogle Scholar
  38. [38]
    Herr HW (1991) Die Rolle der Strahlentherapie beim lokal begrenzten Prostatacarcinom. Urologe A30: 413.Google Scholar
  39. [39]
    Holm HH, Juul N, Pederson JF, et al. (1983) Transperineal 125 iodine seed implantation in prostatic cancer guided by transrectal ultrasound. J Urology 130: 283.Google Scholar
  40. [40]
    Hudes G, Nathan F, Chapman A, Greenberg R, McAleer C (1995) Combined anti-microtubule therapy of metastatic prostate cancer with 96-hr paclitaxel (P) and estramustine (EM): Activity in hormone-refractory disease (HRPC). Proc Ann Meet Am Soc Clin Oncol 14: A 622.Google Scholar
  41. [41]
    Huggins C, Stevens RE, Hodges CV (1941) Studies of prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209–228.CrossRefGoogle Scholar
  42. [42]
    Jacob F, Salomon L, Hoznek A, Bellot J, Antiphon P, Chopin DK, Abbou CC (2000) Laparoscopic radical prostatectomy: Preliminary results. Eur Urol 37(5): 615–620.PubMedCrossRefGoogle Scholar
  43. [43]
    Keuppens FI, Kliment J, Robinson MR, et al. (1997) Final results of a prospective EORTC multicenter randomized phase III study comparing orchidectomy and orchidectomy + mitomycin C in patients with poor prognosis metastatic prostate cancer. J Urol 157(Suppl): 320 (Abstract).Google Scholar
  44. [44]
    Klocker H, Culig Z, Hobisch A, et al. (1996) Androgen receptor alterations in prostatic carcinoma. In: Schnorr D, Loening SA, Dinges S, Budach V (Hrsg) Lokal fortgeschrittenes Prostatacarcinom. Blackwell, Berlin Wien, S. 57–67.Google Scholar
  45. [45]
    Klosterhalfen H, Becker H (1987) 10-Jahres-Ergebnisse einer randomisierten Prospektivstudie beim metastasierten Prostatacarcinom. Akt Urol 18: 234–236.CrossRefGoogle Scholar
  46. [46]
    Kroll JM, Owen JB, Hanks GB (1992) Long term results of treatment of prostate cancer in the USA in 1973, 1978 and 1983. Int J Rad Oncol Biol Phys 24: 147.Google Scholar
  47. [47]
    Labrie F, Dupont A, Bélanger A (1985) A complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. Lippincott, Philadelphia, S. 193–200.Google Scholar
  48. [48]
    Labrie F, Dupont A, Bélanger A, et al. (1983) New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5: 267–275.Google Scholar
  49. [49]
    Leach GE, Cooper JF, Kagan AR, et al. (1982) Radiotherapy for prostatic carcinoma: Post irradiation prostatic biopsy and recurrence. Patterns with long term follow-up. J Urol 128:505.PubMedGoogle Scholar
  50. [50]
    Litwiller S, Djavan B, Klopukh B, Richier JC, Roehrborn CG (1995) Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: Changing trends over a ten year period (1984–1994). Urology 45: 813–822.PubMedCrossRefGoogle Scholar
  51. [51]
    Mackler MA, Liberti JP, Smith MJV, Koontz WW, Prout GR (1972) The effect of orchiectomy and various doses of stilbestrol on plasma testosterone level in patients with carcinoma of the prostate. Invest Urol 9: 423–425.PubMedGoogle Scholar
  52. [52]
    Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR (1992) The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956–961.PubMedGoogle Scholar
  53. [53]
    Myers RP, Flemming TR (1983) Course of localized adenocarcinoma of the prostate treated by radical prostatectomy. Prostate 4: 461.PubMedCrossRefGoogle Scholar
  54. [54]
    Noldus J, Huland H (1996) Die radikale Prostatectomie beim lokalisierten Prostatacarcinom: Literaturübersicht und Erfahrung eines Zentrums. Onkologe 2: 224.CrossRefGoogle Scholar
  55. [55]
    Olson MC, Posniak HV, Fisher SG (1994) Directed and random biopsies of the prostate: Indications based on combined results of transrcctal sonography and prostate-specific antigen density determinations. A J Roentgenol 163: 1407–1411.Google Scholar
  56. [56]
    Parker SL, Tong T, Bolden S, Wingo PA (1996). Cancer statistics. CA 46: 5–27.PubMedGoogle Scholar
  57. [57]
    Partin AW, Oesterling JE (1994) The clinical usefulness of prostate specific antigen. Update J Urol 152: 1358–1368.Google Scholar
  58. [58]
    Perez CA, Walz BJ, Zimuska FR, et al. (1980) Irridation of the cancer of the prostate localized to the pelvis: Analysis of tumor response and prognosis. Int J Rad Oncol Biol Phys 6: 555.CrossRefGoogle Scholar
  59. [59]
    Pienta KJ (1996) Advances in the Treatment of Metastatic Prostate Cancer. Medical Center Press, University of Michigan.Google Scholar
  60. [60]
    Pienta KJ, Lehr JE (1993) Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at nuclear matrix. J Urol 149: 1622–1625.PubMedGoogle Scholar
  61. [61]
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17): 1591–1597.PubMedCrossRefGoogle Scholar
  62. [62]
    Prostate Cancer Trialists’ Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 346: 265–269.Google Scholar
  63. [63]
    Robinson MRG (1993) A further analysis of EORTC-protocol 30805. Orchiectomy vs. orchiectomy plus cyproterone acetate vs. low-dose diethyl stilbestrol. Cancer 72: 3855–3857.PubMedCrossRefGoogle Scholar
  64. [64]
    Rosenzweig KE, Morgan WR, Fischer D, et al. (1992) Prostate specific antigen (PSA) as a marker of disease recurrence in 290 patients with prostate cancer treated with external beam radiation therapy (EBRT). J Urol 147: 447.Google Scholar
  65. [65]
    Schafhauser W, Kühn B, Schwarzmann D (1997) Das Adenokarzinom der Prostata. Klinikarzt 26: 31–40.Google Scholar
  66. [66]
    Schellhammer PF, El-Mahdi AM (1983) Pelvic complications after definitive treatment of prostate cancer by interstitial or external beam radiation. Urology 21: 451–457.PubMedCrossRefGoogle Scholar
  67. [67]
    Schröder FH (1993) Cyproterone acetate-mechanism of action and clinical effectiveness in prostate cancer. Cancer (Suppl) 72: 3810–3815.Google Scholar
  68. [68]
    Schröder FH (1997) Antiandrogen monotherapy-standard treatment for prostate cancer? (Abstract). Internat Symposium Developments in Endocrine Management of Prostate Cancer, Berlin, 27. 06. 1997.Google Scholar
  69. [69]
    Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR (1997) Laparoscopic radical prostatectomy: Initial short-term experience. Urology 50(6): 854–857.PubMedCrossRefGoogle Scholar
  70. [70]
    Simak R, Eisenmenger M, Hainz A, Kratzik C, Marberger M (1993) Is transrectal ultrasonography needed to rule out prostatic cancer with normal findings at digital rectal examination and normal serum prostate-specifc antigen? Eur Urol 24: 474–478.PubMedGoogle Scholar
  71. [71]
    Studer UE (1995) Fortgeschrittenes Prostatakarzinom — welche Hormontherapie wann? Urologe A34: 361–366.Google Scholar
  72. [72]
    Van Poppel H (1996) Patterns of failure in surgically treated patients. In: Petrovich Z, Baert L, Brady LW (eds) Carcinoma of the Prostate. Springer, Berlin.Google Scholar
  73. [73]
    Veenema R, Gursel E, Lattimer J (1977) Radical retropubic prostatectomy for cancer: A 20-year experience. J Urol 117: 330–331.PubMedGoogle Scholar
  74. [74]
    Veterans Administration Cooperative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017.Google Scholar
  75. [75]
    Wächter S, Gerstner N, Dieckmann K, Stampfer M, Hawliczek R, Pötter R (1997) Three-dimensional planned conformai low volume radiotherapy of localized carcinoma of the prostate. Strahlenther Onkol 5: 253–260.CrossRefGoogle Scholar
  76. [76]
    Wallner K (1991) Iodine 125 brachytherapy for early stage prostate cancer: New techniques may achieve better results. Oncology 5: 115–122.PubMedGoogle Scholar
  77. [77]
    Walsh PC (1988) Radical retropubic prostatectomy with reduced morbidity: An anatomic approach. NCI Monogr 7: 133–137.PubMedGoogle Scholar
  78. [78]
    Wingo PA, Tong T, Bolden S (1995) Cancer statistics 1995. Cancer J Clin 45: 8–30.CrossRefGoogle Scholar
  79. [79]
    Yasumoto N, Djavan B, Marberger M, Kumon H (1999) Prostate cancer gene therapy: Outcome of basic research and clinical trials. Tech Urol 5(4): 185–190.Google Scholar
  80. [80]
    Zelefsky MJ, Leibel SA, Gaudin PB (1998) Dose escalation with three-dimensional conformai radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41: 491–500.PubMedCrossRefGoogle Scholar
  81. [81]
    Zlotta AR, Djavan B, Marberger M, Schulman CC (1997) Prostate specific antigen density of the transition zone: A new effective parameter for prostate cancer detection. J Urol 157: 1315–1321.PubMedCrossRefGoogle Scholar
  82. [82]
    Zlotta AR, Djavan B, Petein M, Susani M, Marberger M, Schulman CC (1998) Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen levels below 10ng/ml. J Urol 160: 2089–2095.PubMedCrossRefGoogle Scholar
  83. [83]
    Zlotta AR, Djavan B, Roumeguere T, Marberger M, Schulman CC (1997) Transition zone volume on transrectal ultrasonography is more accurate and reproducible than the total prostate volume. Brit J Urol Suppl 80: 926–930.Google Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Bob Djavan
    • 1
  • Christian Seitz
    • 1
  • Michael Marberger
    • 1
  1. 1.Universitätsklinik für UrologieAllgemeines KrankenhausWienÖsterreich

Personalised recommendations